

Colorectal Cancers: Latest Developments & Future Frontiers

September 27, 2025 ▪ Hyatt Place Historic District ▪ Charleston, SC

Disclosure Statement

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education anyone involved in planning or presenting this educational activity will be required to disclose any financial relationships with any ineligible companies. *An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.* This information is listed below. Any financial relationships with these ineligible companies have been mitigated by the MUSC Office of CME. Speakers who incorporate information about off-label or investigational use of drugs or devices will be asked to disclose that information at the beginning of their presentation. The following information has been disclosed:

Presenters/Planners/Moderators with NO financial relationships with Ineligible Companies:

Toros Dincman, MD, PhD
Colleen Donahue, MD
Virgilio V. George, MD
Alisha Gouridine
Chris Gregory, PhD, PT

Brian Lally, MD
William Lancaster, MD
Lee Putney
Frances Russell
Maggie Westfal, MD

Presenters/Planners/Moderators with financial relationships with Ineligible Companies:

Sunnie Kim, MD

Advisor with Amgen, AstraZeneca, BeOne, BMS, Gilead, Merck

John Strickler, MD

Advisory Board/Consultant for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, MBS, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson & Johnson, Jazz Pharmaceuticals, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics; **Research Funding** with Abbvie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi-Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech; **Stock Options** with Triumvira Immunologics

Namrata Vijayvergia, MD

Consultant with Boehringer Ingelheim, Exelixis, Gilead, Jazz Pharmaceuticals

A Craig Lockhart, MD

Consultant with BeOne Medicines, Merck; **Speaker** with BeOne, Ipsen*; **Research** with Abbvie, Apollo Therapeutics, Merck

*The relationship has ended in the last 24 months.